Showing results (481-490 of 567) with videos related to
Sort By:
Pageof 57
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 25, 2014
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancerR Leibowitz-Amit, A J Templeton, A Omlin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2023
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-UpThomas Powles, Se Hoon Park, Claudia Caserta, et al.Urologic Oncology|February 4, 2012
Summary of the 6th Annual Bladder Cancer Think Tank: new directions in urologic researchRobert S Svatek, Jonathan E Rosenberg, Matthew D Galsky, et al.Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|March 16, 2016
The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysisMadhur Nayan, Bimal Bhindi, Julie L Yu, et al.Future Oncology (London, England)|May 24, 2022
Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trialSumanta K Pal, Diederik M Somford, Petros Grivas, et al.Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 2, 2015
Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranibSuzanne Richter, Jo-An Seah, Gregory R Pond, et al.Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 2, 2025
A population-based analysis of patterns of care in patients with de novo muscle-invasive bladder cancer from Alberta, CanadaNimira S Alimohamed, Geoffrey Gotto, Girish S Kulkarni, et al.Nature Medicine|December 11, 2021
Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trialThomas Powles, Srikala S Sridhar, Yohann Loriot, et al.European Urology Oncology|May 3, 2025
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 TrialPetros Grivas, Jeanny B Aragon-Ching, Joaquim Bellmunt, et al.Nature Nanotechnology|November 22, 2016
Tracking the dynamics of circulating tumour cell phenotypes using nanoparticle-mediated magnetic rankingMahla Poudineh, Peter M Aldridge, Sharif Ahmed, et al.Pageof 57